Buy Combigan

Combigan

Combigan: Eye Care Medication Overview

Combigan is a prescription eye drop that contains two active ingredients: brimonidine tartrate and timolol maleate. It is supplied in a bottle with a concentration of 0.2 % brimonidine / 0.5 % timolol. The product is regulated by the Hong Kong Department of Health and is indicated for the treatment of elevated intra-ocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

How Combigan Works in the Body

• Brimonidine tartrate is an α₂-adrenergic receptor agonist. By stimulating these receptors on ocular blood vessels, it reduces the production of aqueous humour and enhances its outflow, leading to a modest decrease in IOP.
• Timolol maleate is a non-selective β-adrenergic blocker. It lowers aqueous-humour formation by inhibiting β-receptors in the ciliary body.
• The combination provides a dual mechanism: decreased fluid production (timolol) plus increased drainage (brimonidine).
• Onset of IOP reduction typically occurs within 30 minutes after administration, with peak effect around 2 hours. The effect can last up to 12 hours, which is why the dosing schedule is usually twice daily.

Conditions Treated by Combigan

• Primary open-angle glaucoma (POAG)
• Ocular hypertension (OHT)

Both conditions are characterized by elevated IOP that can damage the optic nerve and lead to vision loss if untreated. Combigan is used when monotherapy with either brimonidine or timolol alone does not achieve target IOP levels.

Evaluating Combigan for Your Health Profile

Who Should Use Combigan?

• Adults diagnosed with POAG or OHT who require additional IOP control beyond a single agent.
• Patients who can tolerate both a β-blocker and an α₂-agonist.

Absolute Contraindications

• Known hypersensitivity to brimonidine, timolol, or any component of the formulation.
• Severe sinus bradycardia, atrioventricular block, or overt heart failure (β-blocker effect).
• Children under 12 years of age (insufficient safety data).
• Patients with uncontrolled asthma or severe chronic obstructive pulmonary disease (COPD) due to potential β-blockade of bronchial smooth muscle.

Relative Contraindications

• Moderate renal or hepatic impairment (dose adjustment may be required).
• Pregnancy (category C) and lactation - use only if the potential benefit outweighs risk.
• Use with caution in patients with a history of depression or severe dry eye, as brimonidine can cause ocular discomfort.

Special Populations

• Elderly: May be more sensitive to systemic β-blocker effects; monitor heart rate and blood pressure.
• Patients with respiratory disease: Prefer alternative IOP-lowering agents unless benefits clearly outweigh risks.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Transient ocular burning or stinging at the moment of instillation.
• Dry eye or foreign-body sensation.
• Mild headache.

These effects are usually short-lived and can be mitigated by applying the drop gently and avoiding contact with the eyelid margin.

Serious Adverse Events

• Systemic bradycardia or hypotension (from timolol absorption). Seek medical attention if you experience dizziness, fainting, or unusually slow heart rate.
• Severe allergic reactions such as angio-edema, rash, or swelling of the face.
• Acute angle-closure glaucoma (rare) - sudden eye pain, halos around lights, or vision loss require immediate emergency care.

Drug Interactions

• Systemic β-blockers (e.g., metoprolol, propranolol): Additive cardiac effects; monitor heart rate and blood pressure.
• Calcium channel blockers and antidepressants may also potentiate bradycardia.
• Monoamine oxidase inhibitors (MAOIs): Potential for increased brimonidine levels; caution advised.

Food and Lifestyle Interactions

• No known food-drug interactions.
• Alcohol may enhance the systemic β-blocker effect, potentially leading to greater drowsiness or low blood pressure.
• Driving or operating machinery is generally safe, but be aware of any dizziness that might arise after dosing.

How to Take Combigan

• Standard dosing: One drop in each affected eye twice daily, typically morning and evening, or as directed by your ophthalmologist.
• Administration tips:
• Wash hands before use.
• Tilt the head back, pull down the lower eyelid, and place a single drop without touching the bottle tip to the eye.
• Close the eye gently for about 1 minute; do not blink or rub.
• Missed dose: Administer the missed dose as soon as you remember if it is at least 4 hours before the next scheduled dose. Otherwise, skip it and resume the regular schedule - do not double the dose.
• Overdose: Excessive dosing may cause marked bradycardia, hypotension, or severe ocular irritation. Seek immediate medical assistance.
• Discontinuation: Do not stop abruptly without consulting your eye-care provider, as IOP may rise rapidly. A tapering plan is rarely needed for eye drops but a follow-up IOP check is essential.

Monitoring and Follow-Up

• IOP measurement: Baseline IOP before starting Combigan, then at 1-2 weeks after initiation, and periodically thereafter (often every 3-6 months).
• Cardiovascular assessment: Heart rate and blood pressure should be checked, especially in patients with known cardiac disease or those on other β-blockers.
• Ocular health: Slit-lamp examination for signs of ocular surface irritation or allergic reaction.
• When to call your provider: Sudden vision changes, severe eye pain, symptoms of low blood pressure (e.g., light-headedness), or persistent eye redness.

Storage and Handling

• Keep the bottle at room temperature (15-30 °C), away from direct sunlight and moisture.
• Do not freeze.
• Keep the bottle tightly closed when not in use.
• Discard any remaining solution after 30 days of opening, even if the expiration date has not been reached, to avoid contamination.
• Store out of reach of children; the bottle is child- resistant but not child-proof.

Medication-Specific Glossary

α₂-Adrenergic Agonist

A drug that activates α₂-adrenergic receptors, leading to reduced production of aqueous humour in the eye.

β-Blocker

A medication that blocks β-adrenergic receptors, decreasing heart rate and aqueous-humour formation.

Intra-ocular Pressure (IOP)

The fluid pressure inside the eye; elevated IOP is the main risk factor for glaucoma.

Open-Angle Glaucoma

A chronic eye disease where the drainage angle remains open but outflow is impaired, causing progressive optic nerve damage.

Medical Disclaimer

This article provides educational information about Combigan and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.